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Abstract 
 
Background: Breast cancer is the most common cause of cancer mortality among European women. 
To reduce mortality risk, early detection through mammography screening is recommended from the 
age of 50 onwards. Although timely initiation is crucial for cancer prognosis, the temporal dimension 
has largely been ignored in research. In cross-sectional research designs, it is not clear whether 
reported age differences reflect ‘true’ age effects and/or presumed period effects resulting from 
evolving knowledge and screening programs.  
Methods: We use longitudinal data from the survey of Health, Ageing and Retirement (SHARELIFE, 
2008), which enables to cast light on age differences by providing retrospective information on the 
age at which women commenced regular mammography screening. Moreover, the cross-national 
dimension of the SHARE permits framing the results within the context of nationally implemented 
screening programs. By means of the Kaplan-Meier procedure, we examine age trajectories for five 
10-year birth cohorts in 13 European countries (N = 13 324). 
Results: Birth cohorts show very similar age trajectories for each country. Along with the observation 
that large country differences and country-specific deviations coincide with screening program 
characteristics, this suggests strong period effects related to implemented national screening 
programs. 
Conclusion: Age differences in mammography screening generally reflect the period effects of 
national screening policies. This leaves little room for economic theories about human health capital 
that leave out the institutional context of preventive health care provision.  
 Introduction 
Breast cancer is the most frequently diagnosed form of cancer among European women, accounting 
for 319 900 cases in 2006 (30.9% of all cancer diagnoses). It is the leading cause of death from cancer 
among women, with an estimated mortality rate of 16.7%. Breast cancer will remain an important 
public health issue, given that even more women are likely to be affected in the future due to the 
ageing population [1].  
 
Research has predominantly focused on the role of national programs in reducing the well-
documented socio-economic inequalities in mammography screening [e.g. 2, 3, 4]. In contrast, the 
timely initiation of screening has received much less attention [5], despite its crucial importance for 
cancer prognosis [6]. After all, the stage at diagnosis (or tumour size) is strongly linked to survival [7]. 
Since women aged 50-69 are at the highest risk for breast cancer, both the World Health 
Organization (WHO) and the Council of the European Union [8] recommend that national programs 
target these women for regular check-ups.  
 
In general, age is regarded as a control or a confounding variable, or is used as a proxy for “need” for 
care, because “need” factors are not always apparent [e.g. 3, 9]. Occasionally, age differences are 
theoretically hypothesized based on the economic theory of human health capital [10]. Good health 
is treated as both a consumption commodity (i.e. sick days being a source of disutility) and an 
investment commodity (i.e. the total amount of time available for market and nonmarket activities). 
In the case of medical screening, early detection and intervention of the illness does not only 
improve the disease prognosis as previously mentioned, it can also reduce treatment costs [11]. As 
such, investments and the choice for mammography screening are made in order to optimize their 
utility [9]. During these cost-benefit considerations, women are likely to consider factors other than 
just financial costs such as the fear of false positives [12], pain [13] and overtreatment [14]. With 
regard to age, different hypotheses can be formulated. On the one hand, the returns on investment 
 from preventive screening are hypothesized as being reduced for older women, given that overall 
health deteriorates with increased age and the years that can potentially be saved also declines [15]. 
On the other hand, greater returns on investment can be hypothesized for older women, since they 
face a higher risk of breast cancer [1].  
 
Empirical studies generally report lower engagement in screening among older women [9], but 
confusion remains high. One of the reasons for this is that studies still predominantly rely on cross-
sectional designs, in which women are asked to report whether or not they engaged in screening 
during a prior period, usually two years. This design and question wording render it impossible to 
examine the extent to which age differences reflect ‘true’ age effects rather than age acting as a 
proxy for period effects, which are expected given the changing knowledge over time about breast 
cancer and screening programs. Moreover, this snapshot perspective does not allow study of the 
long-term use of mammography screening at the recommended regular intervals of two years [16]. 
The retrospective data from the Survey of Health, Ageing and Retirement (SHARE, 2008-2009, known 
as SHARELIFE), provides information about the age at which women commenced regular 
mammography screening. This allows to discern largely age effects from broader period effects and 
includes the notion of regularity. 
In addition, the cross-national dimension of the population-based data enables us to frame potential 
period effects within the context of nationally implemented screening programs. These programs can 
reduce or eliminate financial and other costs and therefore change age-eligible women’s’ cost-
benefit analysis. Despite general guidelines [16], European countries differ greatly in screening 
strategies (left-hand columns, Table 1). Most have now organized national population-based 
programs, in which women are personally offered screening on a regular basis, mostly every two or 
three years from the age of 50 onwards. However, in Switzerland and Italy, programs of this nature 
have only been implemented in some regions [5, 8, 17], and other countries, such as Austria and 
Greece, still rely completely on opportunistic screening, where individuals request screening 
 themselves or are recommended to do so by health advisors [18]. Further, large differences exist in 
the organizational characteristics of programs, their implementation stage, the method of offering 
screening, and the participation rate [5, 8, 17].  
By comparing different institutional contexts, we highlight the supply side, which influences 
preventive health care use along with frequently-cited individual factors such as socio-economic 
status [19]. To date, seven studies have addressed cross-national differences in mammography 
screening in Europe, using population-based data from the World Health Survey (2002) [20], the 
Eurobarometer (66.2, 2006) [21], the first two waves of the SHARE (2004/2006) [3, 9, 22], and 
SHARELIFE [23, 24]. Except for the last studies, all have focused on socio-economic inequalities using 
cross-sectional data, rendering the study of age differences in regular screening problematic. Also 
using data from SHARELIFE, Sirven and Or (27) very briefly mention age differences in the 
commencement of regular mammography screening for three large birth cohorts and four large 
European regions. This current paper aims to provide a more in-depth discussion, paying explicit 
attention to country differences and their associations with the characteristics of national screening 
policies.  
Data 
SHARE is a multidisciplinary and cross-national panel database on health, socio-economic status, and 
social and family networks. Details about the sampling procedure can be found elsewhere [25], but in 
general it consists of probability samples, drawn from population registers or from multistage 
sampling. Respondents aged 50 or above together with their partner (and other household members 
in wave 1, aged at least 50) were interviewed face-to-face using structured computerized 
questionnaires. This study uses data from the third wave (SHARELIFE, 2008-2009), in which 
retrospective information was collected about preventive health care use during the life course, 
among other items. To improve recall of retrospective data, a life history calendar (LHC) was used. 
The respondent’s life is represented graphically by a grid that is completed during the interview [26]. 
 Special efforts were made to reduce attrition and attain high retention rates throughout the different 
waves. This has led to an overall retention rate of 71% [25] ((for details see [27]). The household 
response rate in the first wave was on average 62% and country variation reflected patterns from 
other international surveys [25]. Individual response rates amount to 85% on average (for country-
specific figures see website: http://www.share-project.org/data-access-
documentation/sample.html). Data was collected in six Western European countries (Belgium, 
France, The Netherlands, Germany, Switzerland, and Austria), two Northern European countries 
(Denmark and Sweden), three Southern European countries (Spain, Greece, and Italy) and two 
countries in Eastern Europe (Poland and The Czech Republic). Because of the focus on preventive 
mammography screening, a small number of women who were diagnosed with breast cancer during 
their lives are excluded from the sample (N = 285; 2.0%). This information was retrieved from wave 1 
(2004) and wave 2 (2006). There is only a small amount of information missing for mammography 
screening practices (5.3%) and this is therefore deleted listwise.  
Measurements 
Regular mammography screening initiation 
Our dependent variable, the commencement of regular mammography screening, is retrieved from 
the question ‘In which year did you start having mammograms regularly?’ given to all women who 




We construct five birth cohorts from 1910 to after 1949 in ten-year intervals. These cohorts act as 
proxy for period effects. Depending on their birth cohort, women were the recommended age for 
screening and/or the eligible age for population-based screening programs in different time periods.  
 Methods 
We apply event history analysis, to model the time until women commenced regular mammography 
screening. The end of the risk period is defined either by the time the event occurred (i.e. the age of 
commencing regular mammography screening) or by the time the individual is censored (i.e. those 
who did not experience the event during the observation period) [28]. Here, women who did not 
engage in mammography screening are censored at the time of the retrospective data collection in 
SHARELIFE (2008 or 2009). Unlike standard statistical methods such as linear or logistic regression, 
event history analysis can adequately deal with censoring. The Nelson-Aalen method is used to 
calculate the cumulative hazard function, which assesses at each point in time the amount of 
accumulated risk between the beginning of the examined period and each observed event time. 
Exploring behavior graphically over time allows us to retrieve information about the shape of the 
underlying hazard function [28]. The graphs will thus show at each age, the accumulated risk factor 
for women of a specific birth cohort to commence regular screening. A log rank test is performed to 
assess whether these cumulative hazards differ significantly by birth cohorts. Also, simple descriptive 
statistics are calculated to give an overview of the proportion of women in each country that ever 
commenced regular screening. All analyses are carried out in Stata 11. 
Results  
First, we focus on the age trajectories. Figure 1 shows that the cumulative hazard increases at a 
similar rate across age in all countries, except for a large increase at the age of 50, which reflects the 
generally recommended age for commencing screening. A notable exception is found for Sweden, 
where the likelihood of screening increases sharply among 40-year-old women. This is not that 
remarkable, as about 65% of Swedish counties start offering screening for women at the age of 40 
[8].  
(figure 1 around here) 
 To find out whether these age trajectories differ according to birth cohorts, we turn to the country-
specific figures (Figure 2a-m). For all countries, women in younger birth cohorts have a higher 
cumulative hazard and are thus more likely to commence regular screening at some age (log-rank, 
p<0.001 for all countries). For the three youngest cohorts in particular, the hazard for screening 
increases at the same rate and a notable increase is observed at the age of 50, except for Austria, 
Greece, Germany, and Poland. This suggest that there are no ‘true’ age- effects, so that age is not a 
crucial factor that is taken into consideration when deciding about screening. Rather this points to 
broader period-effects, especially because features of national screening programs can again be 
linked to these exceptions and also to a great extent to the large country-variation in the overall 
take-up of screening.  
(figure 2 a-m around here) 
In Austria and Greece, an organized program is absent, while the implementation in Poland (2007) 
was too close to the data collection in 2008-2009 to be reflected in the figures. Similarly, in Germany, 
the roll-out of the national screening program started in 2005, but it was completed only in 2009 
[29]. In Denmark, the national program only commenced in December 2007, but here an increase at 
the age of 50 is still notable. This can be explained by regional programs, which have covered 20% of 
Danish women aged between 50 and 69 since 1991 [30]. In Austria, a spontaneous screening 
program for women aged 35 years or above started in Tyrol in 1993. Here, screening is free of charge 
for women from the age of 40 [31]. The sharp increase in screening at the age of 40 for women born 
after 1949 in Austria is probably a reflection of this program or the example it has set. An increase at 
45 years of age is found for Spanish and Czech women born after 1949. Some Spanish regions start 
offering screening to women aged 45 [32] and the national program in the Czech Republic includes 
women from the age of 45 onwards.  
Next, countries differ largely in how high the cumulative hazards are across age (figure 1). This 
indicates that at all ages, the take-up of regular mammography screening differs strongly between 
 European countries, which is also reflected in the general figures in table 1. The lowest proportion is 
found in Denmark (29.3%), while Swedish women are the most likely to engage in regular screening 
(89.8%). It is remarkable that these extremes are both in the Northern European region, which is 
generally considered as universally the best performing with regard to health, due to relatively 
generous and universal welfare provision [33]. However, this is not so surprising given the long-term 
implementation of a national screening program in Sweden, in contrast to Denmark (see table 1)).  
After Sweden, The Netherlands has the longest running program and the second-highest proportion 
of regular screeners (84.9%). On the other hand, the least regular screeners are found in Denmark 
(29.3%), Poland (40.1%), Germany (48.2%), Greece (47.5%) and Switzerland (48.9%). A national 
program was implemented too closely to the SHARELIFE data collection for reflection in the figures of 
Denmark and Poland, while it is absent in the two latter countries. However, the absence of a 
national program does not necessarily entail that many women forgo mammography screenings as 
for example in Austria a large volume of opportunistic screening is notable (64.7%). In Italy, regional 
programs have taken off since 1985 [17], so that in 2007 at least one pilot population-based program 
in all Italian regions has been realized [8]. Accordingly, the share of women with regular screenings in 
Italy (62.4%) is similar to its neighboring country Spain, where a national program was launched in 
1990 (66.5%). Although Germany and France both had their national program only recently 
implemented in 2004, the number of regular screeners differs considerably (48.2% and 77.4% 
respectively). This could be associated with the long-standing practice since 1971 to offer yearly 
gynecological ‘cancer early detection exams’ to German women from the age of 30 onwards. Breasts 
are inspected and palpated by medical doctors who also give instructions for breast self-examination 
[34]. Czech women rank sixth, with 56.7% undergoing regular screenings.  
(table 1 around here) 
 Discussion 
The aim of this paper is to move the debate on age differences in mammography screening forward 
using data from SHARELIFE. This dataset contains unique information for 13 European countries, 
which is both longitudinal and population based. Several meaningful observations strongly suggest 
that age differences as reported in cross-sectional surveys are no ‘true’ effects of age but reflect 
period effects. Neither hypothesis with regard to age as a component of cost-benefit considerations 
of mammography screening seem to hold.  
Overall, older birth cohorts engage less in screening in all the countries. However, when they do, 
they do not initiate screening at an considerably older age than younger cohorts. It is rather clear 
that the fewer uptake of mammography screening by older women over the course of their lives is 
inextricably bound up with the evolution in knowledge about breast cancer [see e.g. 35] and the 
discussion and implementation of screening policies. The crucial role of screening policies is also 
reflected in the large country variation in screening as well in the observation that exceptions can be 
linked to features of national screening programs.  
Even within the same European region, large country differences are notable in the take up of 
mammography screening. The World Health Survey (WHS) 2002 revealed similar results [20], 
although the ranking of prevalence rates shows some differences. For five countries (Belgium, 
Denmark, Sweden, Greece, and the Czech Republic) proportions are lower in the WHS than in 
SHARELIFE, while for the other five countries with available data (France, Germany, Austria, Spain, 
and Italy), higher proportions are noted. For France, this might be related to the introduction of a 
national program (2004) between the data collections of the two surveys. However, in other 
countries such as Spain this might not be the case, given the early implementation of the program 
there in 1990. Instead, as suggested by Braillon [36], cross-sectional data might overestimate the 
quality of the programs. The one other cross-national study that did not use data from SHARE [21], 
only scrutinized determinants of screening for a dichotomous grouping of countries based on 
 opportunistic versus nationally organized programs. Our results suggest that important country-
specific characteristics are thereby overlooked.  
The SHARELIFE also questioned the reasons for not taking up mammography. These reasons differ 
strongly between countries [for numbers see 24, 37] and can again been linked to screening policies. 
Respondents stated that information was lacking and that screening was not affordable or available 
in countries without a national program (Austria and Greece) or only a recently implemented 
program (Germany and Poland). In countries with only regional coverage (Italy and Switzerland), 
respondents stated that they did not engage in screening because of a lack of information and 
financial means. In the Netherlands and Sweden, the two countries with the highest screening rates, 
none of the aforementioned perceived barriers were indicated. Instead, only the belief that 
screening is not necessary was found to be significantly related to not participating [37]. 
The fact that age trajectories in screening appear relatively universal for all countries, despite the 
varying perceived ‘costs’ of screening, corroborates the contention that age differences are largely 
attributable to the period effects of national policies. These period effects are mirrored in cross-
sectional studies that have reported lower screening rates above the age of 60 [2] or 65 [3, 9]. 
Similarly, longitudinal studies such as that of Puddu and colleagues [4], report important period 
effects in terms of an increase in screening over a three-year period among women aged 60 to 69.  
Before turning to the conclusion, two limitations should be acknowledged. First, retrospective data 
may raise some concerns regarding recall bias. However, SHARE took this concern seriously. In 
addition to the measures to minimize bias at the time of data collection, quality checks were 
conducted on the respective data. Although more research is needed, strong consistency has already 
been found for personal events [38]. The second limitation concerns the question wordings regarding 
mammography screening. It is impossible to discern fully whether women started mammography 
screening for preventive purposes only or for other reasons. Data limitations hinder us from 
discerning the motivations of women to commence screening. A family history of breast cancer is 
 related to perceived risk of the disease, which in turn impacts on the commencement of 
mammography screening [39]. However, the information on health history enables us to exclude 
women diagnosed with breast cancer.  
This study illustrates the potential of applying a longitudinal perspective in cross-national 
comparative research on health. For both policy makers and researchers, timeliness deserves further 
attention, even more so for preventive services that require already starting routine check-ups in 
childhood, such as dental care [40]. In sum, cross-sectional age differences in mammography 
screening generally reflect the period effects of national screening policies. This leaves little room for 
economic theories about human health capital that ignore the institutional context of preventive 
health care provision.  
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Keypoints 
What is already known on this subject? 
1. The uptake of mammography screenings differs largely between countries and socio-economic 
groups. 
 2. Little is known about the age of commencement of regular screenings. In a cross-sectional design 
it is impossible to discern age effects from period effects related to evolving knowledge and the 
implementation of national screening programs. 
What this study adds? 
1. By means of retrospective information of the SHARELIFE on the age of screening initiation, age 
trajectories are calculated for different birth cohorts in 13 European countries.  
2. In all 13 European countries, age trajectories seem very similar for all birth cohorts, which suggests 
strong period effects rather than ‘true’ age effects.     
3. Besides, strong period-effects are reflected in the large between-country variation in screening 
uptake as well as in country-specific deviations.  
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Table 1: Mammography screening in 13 European countries 
Characteristics of breast cancer screening policies 
Number and % of regular 














Sweden National 1986 40/50-69/74 748 89.8% 
The Netherlands National 1989 50-75  1066 84.9% 
Spain National 1990 45/50-64/69 1020 66.5% 
Belgium National 2001 50-69 1425 71.6% 
The Czech Republic National 2002 45-69 997 56.7% 
France National 2004 50-74 1216 77.4% 
Germany National 2005  50-69 920 48.2% 
Poland  National 2007 50-69 944 40.1% 
Denmark National 2008  50-69 1068 29.3% 
Italy Regional n.a. 45/50-69 1292 62.4% 
Switzerland Regional n.a. 50-70 665 48.9% 
Austria No n.a. n.a. 425 64.7% 
Greece No n.a. n.a. 1538 47.5% 
 
Legends for illustrations 
 
Figure 1: Cumulative hazard function for mammography screening initiation per country (Nelson-
Aalen estimates)  
 
Figure 2 (a-m): Country-specific cumulative hazard function for mammography screening initiation 
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